thromboembolism

Summary

Summary: Obstruction of a vessel by a blood clot that has been transported from a distant site by the blood stream.

Top Publications

  1. doi Apixaban versus warfarin in patients with atrial fibrillation
    Christopher B Granger
    Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27715, USA
    N Engl J Med 365:981-92. 2011
  2. doi Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation
    Gregory Y H Lip
    University of Birmingham Centre for Cardiovascular Sciences, City Hospital, Birmingham, UK
    Chest 137:263-72. 2010
  3. pmc The net clinical benefit of warfarin anticoagulation in atrial fibrillation
    Daniel E Singer
    Massachusetts General Hospital, Boston, Massachussetts 02114, USA
    Ann Intern Med 151:297-305. 2009
  4. doi Canadian Cardiovascular Society atrial fibrillation guidelines 2010: prevention of stroke and systemic thromboembolism in atrial fibrillation and flutter
    John A Cairns
    University of British Columbia, Vancouver, British Columbia, Canada
    Can J Cardiol 27:74-90. 2011
  5. ncbi Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial
    Bengt I Eriksson
    Department of Orthopaedic Surgery, Sahlgrenska University Hospital Ostra, Gothenburg, Sweden
    Lancet 370:949-56. 2007
  6. pmc Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study
    Jonas Bjerring Olesen
    Department of Cardiology, Copenhagen University Hospital Gentofte, 2900 Hellerup, Denmark
    BMJ 342:d124. 2011
  7. ncbi Prognosis of cancers associated with venous thromboembolism
    H T Sørensen
    Department of Clinical Epidemiology, Aarhus University Hospital, Denmark
    N Engl J Med 343:1846-50. 2000
  8. doi Novel oral factor Xa and thrombin inhibitors in the management of thromboembolism
    Bengt I Eriksson
    Department of Orthopaedics, Sahlgrenska University Hospital, Molndal, Sweden
    Annu Rev Med 62:41-57. 2011
  9. pmc Gender differences in the risk of ischemic stroke and peripheral embolism in atrial fibrillation: the AnTicoagulation and Risk factors In Atrial fibrillation (ATRIA) study
    Margaret C Fang
    University of California, San Francisco, CA 94143, USA
    Circulation 112:1687-91. 2005
  10. doi Stroke and thromboembolism in atrial fibrillation: a systematic review of stroke risk factors, risk stratification schema and cost effectiveness data
    Michael Hughes
    National Collaborating Center for Chronic Conditions, Royal College of Physicians, London, UK
    Thromb Haemost 99:295-304. 2008

Research Grants

  1. Effectiveness and Safety of Antithrombotic Strategies after Joint Replacement
    Elaine Hylek; Fiscal Year: 2013
  2. Microvascular Dysfunction in Hyperhomocysteinemia
    Shawn E Bearden; Fiscal Year: 2012
  3. Role of Lipoproteins in Chagasic heart disease
    JYOTHI FALGUNI NAGAJYOTHI; Fiscal Year: 2013
  4. Anti-Phospholipid Multiplex For Pathologic Epitopes
    Paul O Neilsen; Fiscal Year: 2010
  5. Reasons for Racial Disparities in Venous Thromboembolism
    NEIL ADRIAN ZAKAI; Fiscal Year: 2010
  6. FOCUS
    JEFFREY LEE CARSON; Fiscal Year: 2011
  7. Recombinant and Chemo-/Bio-Orthogonal Synthesis of Liposomal Thrombomodulin
    Xue Long Sun; Fiscal Year: 2013
  8. Smooth Muscle Cell Tissue Factor and Cardiovascular Disease
    Mark B Taubman; Fiscal Year: 2013
  9. Physiology and Molecular Biology of Factor XI
    David Gailani; Fiscal Year: 2013
  10. Factor XI in Thrombosis
    David Gailani; Fiscal Year: 2013

Detail Information

Publications388 found, 100 shown here

  1. doi Apixaban versus warfarin in patients with atrial fibrillation
    Christopher B Granger
    Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27715, USA
    N Engl J Med 365:981-92. 2011
    ..Apixaban is a novel oral direct factor Xa inhibitor that has been shown to reduce the risk of stroke in a similar population in comparison with aspirin...
  2. doi Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation
    Gregory Y H Lip
    University of Birmingham Centre for Cardiovascular Sciences, City Hospital, Birmingham, UK
    Chest 137:263-72. 2010
    Contemporary clinical risk stratification schemata for predicting stroke and thromboembolism (TE) in patients with atrial fibrillation (AF) are largely derived from risk factors identified from trial cohorts...
  3. pmc The net clinical benefit of warfarin anticoagulation in atrial fibrillation
    Daniel E Singer
    Massachusetts General Hospital, Boston, Massachussetts 02114, USA
    Ann Intern Med 151:297-305. 2009
    ..These guidelines rely on ischemic stroke rates observed in older trials and do not explicitly account for increased risk for hemorrhage...
  4. doi Canadian Cardiovascular Society atrial fibrillation guidelines 2010: prevention of stroke and systemic thromboembolism in atrial fibrillation and flutter
    John A Cairns
    University of British Columbia, Vancouver, British Columbia, Canada
    Can J Cardiol 27:74-90. 2011
    ..Alternatives to antithrombotic therapies are briefly discussed...
  5. ncbi Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial
    Bengt I Eriksson
    Department of Orthopaedic Surgery, Sahlgrenska University Hospital Ostra, Gothenburg, Sweden
    Lancet 370:949-56. 2007
    After hip replacement surgery, prophylaxis following discharge from hospital is recommended to reduce the risk of venous thromboembolism. Our aim was to assess the oral, direct thrombin inhibitor dabigatran etexilate for such prophylaxis.
  6. pmc Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study
    Jonas Bjerring Olesen
    Department of Cardiology, Copenhagen University Hospital Gentofte, 2900 Hellerup, Denmark
    BMJ 342:d124. 2011
    ..Hypertension, Age ≥ 75 years, Diabetes, previous Stroke) score and the CHA(2)DS(2)-VASc (CHA(2)DS(2)-Vascular disease, Age 65-74 years, Sex category) score and to calculate the capability of the schemes to predict thromboembolism.
  7. ncbi Prognosis of cancers associated with venous thromboembolism
    H T Sørensen
    Department of Clinical Epidemiology, Aarhus University Hospital, Denmark
    N Engl J Med 343:1846-50. 2000
    Little is known about the prognosis of cancer discovered during or after an episode of venous thromboembolism.
  8. doi Novel oral factor Xa and thrombin inhibitors in the management of thromboembolism
    Bengt I Eriksson
    Department of Orthopaedics, Sahlgrenska University Hospital, Molndal, Sweden
    Annu Rev Med 62:41-57. 2011
    ..Dabigatran and rivaroxaban are approved in more than 70 countries for prevention of venous thromboembolism in patients undergoing elective hip or knee arthroplasty, and apixaban is being considered for approval by ..
  9. pmc Gender differences in the risk of ischemic stroke and peripheral embolism in atrial fibrillation: the AnTicoagulation and Risk factors In Atrial fibrillation (ATRIA) study
    Margaret C Fang
    University of California, San Francisco, CA 94143, USA
    Circulation 112:1687-91. 2005
    Previous studies provide conflicting results about whether women are at higher risk than men for thromboembolism in the setting of atrial fibrillation (AF)...
  10. doi Stroke and thromboembolism in atrial fibrillation: a systematic review of stroke risk factors, risk stratification schema and cost effectiveness data
    Michael Hughes
    National Collaborating Center for Chronic Conditions, Royal College of Physicians, London, UK
    Thromb Haemost 99:295-304. 2008
    ..The appropriate administration of thromboprophylaxis in AF patients would need to balance the risks and benefits of antithrombotic therapy with its cost-effectiveness...
  11. ncbi Electronic alerts to prevent venous thromboembolism among hospitalized patients
    Nils Kucher
    Department of Medicine, Cardiovascular Division, Harvard Medical School and Brigham and Women s Hospital, Boston, MA 02115, USA
    N Engl J Med 352:969-77. 2005
    ..We hypothesized that the use of a computer-alert program to encourage prophylaxis might reduce the frequency of deep-vein thrombosis among high-risk hospitalized patients...
  12. pmc Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial
    Alexander T Cohen
    Department of Surgery, Guy s, King s, and St Thomas s School of Medicine, London SE5 9PJ
    BMJ 332:325-9. 2006
    To determine the efficacy and safety of the anticoagulant fondaparinux in older acute medical inpatients at moderate to high risk of venous thromboembolism.
  13. ncbi Venous thromboembolism prophylaxis in acutely ill hospitalized medical patients: findings from the International Medical Prevention Registry on Venous Thromboembolism
    Victor F Tapson
    Division of Pulmonary and Critical Care, Box 31175, Room 351 Bell Building, Duke University Medical Center, Durham, NC 27710, USA
    Chest 132:936-45. 2007
    Evidence-based guidelines recommend that acutely ill hospitalized medical patients who are at risk of venous thromboembolism (VTE) should receive prophylaxis...
  14. doi The role of ethnicity, age and gender in venous thromboembolism
    Martina Montagnana
    Sezione di Chimica Clinica, Dipartimento di Scienze Morfologico Biomediche, Universita di Verona, Ospedale Policlinico G B Rossi, Piazzale Scuro, Verona, Italy
    J Thromb Thrombolysis 29:489-96. 2010
    Venous thromboembolism, including both deep venous thrombosis and pulmonary embolism, is the leading cause of preventable in-hospital mortality...
  15. ncbi Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis
    Paolo Prandoni
    Department of Medical and Surgical Sciences, Second Chair of Internal Medicine, University Hospital of Padua, Italy
    Blood 100:3484-8. 2002
    ..sought to determine whether in thrombosis patients those with cancer have a higher risk for recurrent venous thromboembolism or bleeding during anticoagulant treatment than those without cancer...
  16. ncbi Venous thromboembolism during pregnancy and the postpartum period: incidence, risk factors, and mortality
    Andra H James
    Division of Maternal Fetal Medicine, Duke University Medical Center, Durham, NC 27710, USA
    Am J Obstet Gynecol 194:1311-5. 2006
    The purpose of this study was to estimate the incidence, risk factors, and mortality from pregnancy-related venous thromboembolism.
  17. ncbi Venous thromboembolism in young patients from western India: a study
    K Ghosh
    Institute of Immunohaematology (Indian Council of Medical Research) KEM Hospital Campus, Parel, Mumbai, India
    Clin Appl Thromb Hemost 7:158-65. 2001
    ..8% of the patients had homozygosity for the MTHFR C677T polymorphism...
  18. ncbi Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies
    Alexander G G Turpie
    Department of Medicine, Hamilton Health Sciences General Hospital, 237 Barton, Hamilton, Ontario, Canada L8L 2X2
    Arch Intern Med 162:1833-40. 2002
    Orthopedic surgery remains a condition at high risk of venous thromboembolism (VTE)...
  19. ncbi Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial
    S Bertil Olsson
    Department of Cardiology, University Hospital, Lund SE 221 85, Sweden
    Lancet 362:1691-8. 2003
    ..The oral direct thrombin inhibitor ximelagatran represents a potential alternative. We aimed to establish whether ximelagatran is non-inferior to warfarin, within a margin of 2% per year, for prevention of stroke and systemic embolism...
  20. ncbi Treatment patterns and real-world effectiveness of warfarin in nonvalvular atrial fibrillation within a managed care system
    Theodore Darkow
    Health Informatics and Outcomes Research Division, Prescription Solutions, Costa Mesa, CA 92626, USA
    Curr Med Res Opin 21:1583-94. 2005
    ....
  21. ncbi Incidence of recurrent venous thromboembolism in relation to clinical and thrombophilic risk factors: prospective cohort study
    Trevor Baglin
    Department of Haematology, Addenbrooke s NHS Trust, Cambridge, UK
    Lancet 362:523-6. 2003
    Stratification for risk of recurrence after a first episode of venous thromboembolism (VTE) would affect the duration of anticoagulant therapy...
  22. ncbi Risk factors for venous thromboembolism in hospitalized patients with acute medical illness: analysis of the MEDENOX Study
    Raza Alikhan
    Academic Department of Surgery, Guy s, King s, and St Thomas School of Medicine, London, England
    Arch Intern Med 164:963-8. 2004
    There is limited information about risk factors for venous thromboembolism (VTE) in acutely ill hospitalized general medical patients.
  23. doi Patterns in neurosurgical adverse events: intracranial neoplasm surgery
    Judith M Wong
    Department of Health Policy and Management, Harvard School of Public Health, Brigham and Women s Hospital, Street, Boston, Massachusetts 02115, USA
    Neurosurg Focus 33:E16. 2012
    ....
  24. ncbi The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy
    Jack Ansell
    Department of Medicine, Boston University Medical Center, 88 E Newton St, Boston, MA 02118, USA
    Chest 126:204S-233S. 2004
    ..For the management of patients with a low risk of thromboembolism, we suggest stopping warfarin therapy approximately 4 days before they undergo surgery (Grade 2C)...
  25. ncbi Dalteparin for prevention of catheter-related complications in cancer patients with central venous catheters: final results of a double-blind, placebo-controlled phase III trial
    M Karthaus
    Evang Johannes Krankenhaus, Medizinische Klinik, Bielefeld, Germany
    Ann Oncol 17:289-96. 2006
    ..This prospective, double-blind, placebo-controlled, multicenter study evaluated whether prophylactic treatment with a low molecular weight heparin could prevent clinically relevant catheter-related thrombosis...
  26. pmc The impact of venous thromboembolism on risk of death or hemorrhage in older cancer patients
    Cary P Gross
    Section of General Internal Medicine, Yale University School of Medicine, New Haven, CT, USA
    J Gen Intern Med 22:321-6. 2007
    Among older cancer patients, there is uncertainty about the degree to which venous thromboembolism (VTE) and its treatment increase the risk of death or major hemorrhage.
  27. ncbi Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran
    Sam Schulman
    Coagulation Unit, Department of Medicine, Karolinska Hospital, Stockholm, Sweden
    N Engl J Med 349:1713-21. 2003
    For many patients with venous thromboembolism, secondary prevention with vitamin K antagonists is not extended beyond six months, since the risk of recurrence may be outweighed by the risk of major bleeding.
  28. ncbi Efficacy and safety of periprocedural dabigatran in patients undergoing catheter ablation of atrial fibrillation
    Kenichi Kaseno
    Division of Cardiology, Gunma Prefectural Cardiovascular Center, 3 12 Kameizumi, Maebashi 371 0004, Japan
    Circ J 76:2337-42. 2012
    ..Few studies, however, have evaluated the efficacy and safety of periprocedural dabigatran in AF ablation...
  29. pmc The what, why and how of aromatase inhibitors: hormonal agents for treatment and prevention of breast cancer
    C J Fabian
    Breast Cancer Prevention Center, Division of Clinical Oncology, Department of Internal Medicine, University of Kansas Medical Center, Kansas City, KS 66160 7418, USA
    Int J Clin Pract 61:2051-63. 2007
    ..an AI for risk reduction and (ii) recognise and manage AI-associated adverse events. The primary purpose of this review is to help internists with these two tasks...
  30. ncbi Cancer and venous thromboembolism
    Paolo Prandoni
    Department of Medical and Surgical Sciences, Second Chair of Internal Medicine, University of Padua, Padua, Italy
    Lancet Oncol 6:401-10. 2005
    Venous thromboembolism occurs commonly in patients with cancer. The pathogenetic mechanisms of thrombosis involve a complex interaction between tumour cells, the haemostatic system, and characteristics of the patient...
  31. ncbi Risk of thromboembolism in 14,000 individuals with coeliac disease
    Jonas F Ludvigsson
    Department of Paediatrics, Orebro University Hospital, and Department of Medicine, Clinical Epidemiology Unit, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden
    Br J Haematol 139:121-7. 2007
    The risk of venous thromboembolism (VTE) was examined in individuals with coeliac disease (CD). The Swedish national inpatient register was used to identify 14 207 individuals with a diagnosis of CD (1964-2003)...
  32. doi Thromboembolic complications of elective coil embolization of unruptured aneurysms: the effect of oral antiplatelet preparation on periprocedural thromboembolic complication
    Gyojun Hwang
    Department of Neurosurgery, Chuncheon Sacred Heart Hospital, Hallym University, Chuncheon, Korea
    Neurosurgery 67:743-8; discussion 748. 2010
    ..We retrospectively evaluated whether antiplatelet preparation lowered the thromboembolic complication rate during the perioperative period...
  33. ncbi Post-thrombotic syndrome, recurrence, and death 10 years after the first episode of venous thromboembolism treated with warfarin for 6 weeks or 6 months
    S Schulman
    Department of Hematology, Coagulation Unit, Karolinska University Hospital, Stockholm, Sweden
    J Thromb Haemost 4:734-42. 2006
    The influence of the duration of anticoagulant therapy after venous thromboembolism (VTE) on the long-term morbidity and mortality is unclear.
  34. doi Pharmacogenetic testing of CYP2C9 and VKORC1 alleles for warfarin
    David A Flockhart
    Indiana University School of Medicine, Indianapolis, Indiana, USA
    Genet Med 10:139-50. 2008
    ....
  35. pmc Venous thromboembolism and survival in patients with high-grade glioma
    Ralph Simanek
    Division of Haematology and Haemostaseology, Department of Internal Medicine I, Medical University Vienna, Vienna, Austria
    Neuro Oncol 9:89-95. 2007
    ..particularly patients with high-grade glioma (HGG; WHO grade III/IV), have an increased risk of venous thromboembolism (VTE). It has been suggested that VTE predicts survival in cancer patients...
  36. ncbi BAY 59-7939: an oral, direct factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II dose-ranging study
    A G G Turpie
    HHS General Hospital, Hamilton, Canada
    J Thromb Haemost 3:2479-86. 2005
    BAY 59-7939, a novel, oral, direct factor Xa inhibitor, is in clinical development for the prevention of venous thromboembolism (VTE), a frequent complication following orthopaedic surgery.
  37. ncbi Oral, direct Factor Xa inhibition with BAY 59-7939 for the prevention of venous thromboembolism after total hip replacement
    B I Eriksson
    Sahlgrenska University HospitalOstra, Gothenburg, Sweden
    J Thromb Haemost 4:121-8. 2006
    ..Joint replacement surgery is an appropriate model for dose-ranging studies investigating new anticoagulants...
  38. ncbi Risk of nonfatal venous thromboembolism with oral contraceptives containing norgestimate or desogestrel compared with oral contraceptives containing levonorgestrel
    Susan S Jick
    Boston Collaborative Drug Surveillance Program, Boston University School of Medicine, Lexington, MA 02421, USA
    Contraception 73:566-70. 2006
    ..contraceptives (OCs) containing the progestins gestodene and desogestrel have about twice the risk for venous thromboembolism (VTE) compared to users of older OCs containing levonorgestrel...
  39. doi Venous thromboembolism during active disease and remission in inflammatory bowel disease: a cohort study
    Matthew J Grainge
    Division of Epidemiology and Public Health, University of Nottingham, Nottingham, UK
    Lancet 375:657-63. 2010
    ..bowel disease who develop deep vein thrombosis or pulmonary embolism often have active disease at the time of thromboembolism. We therefore aimed to quantify the risk of venous thromboembolism prospectively during different activity ..
  40. ncbi Comparison of 1 month with 3 months of anticoagulation for a first episode of venous thromboembolism associated with a transient risk factor
    C Kearon
    McMaster University, Hamilton, Ontario, Canada
    J Thromb Haemost 2:743-9. 2004
    The risk of recurrence is lower after treatment of an episode of venous thromboembolism associated with a transient risk factor, such as recent surgery, than after an episode associated with a permanent, or no, risk factor...
  41. ncbi Risk of pregnancy-associated recurrent venous thromboembolism in women with a history of venous thrombosis
    I Pabinger
    Department of Internal Medicine I, Division of Haematology and Blood Coagulation, Medical University, Vienna, Austria
    J Thromb Haemost 3:949-54. 2005
    Limited data exist on the risk of pregnancy-associated venous thromboembolism (VTE) in women with a history of VTE.
  42. doi Feasibility and safety of dabigatran versus warfarin for periprocedural anticoagulation in patients undergoing radiofrequency ablation for atrial fibrillation: results from a multicenter prospective registry
    Dhanunjaya Lakkireddy
    Division of Cardiovascular Diseases, Cardiovascular Research Institute, Mid America Cardiology, University of Kansas Hospital and Medical Center, 3901 Rainbow Boulevard, Kansas City, KS 66160 7200, USA
    J Am Coll Cardiol 59:1168-74. 2012
    ..The purpose of this study was to evaluate the feasibility and safety of periprocedural dabigatran during atrial fibrillation (AF) ablation...
  43. doi The use of dabigatran immediately after atrial fibrillation ablation
    Roger A Winkle
    Cardiovascular Medicine and Cardiac Arrhythmias, E Palo Alto, Sequoia Hospital, Redwood City, California, USA
    J Cardiovasc Electrophysiol 23:264-8. 2012
    ..Dabigatran is a new anticoagulant and may be useful after AF ablation to prevent thromboembolic events...
  44. ncbi Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study
    Marianne Canonico
    INSERM Unit 780, Cardiovascular Epidemiology Section, 16 Avenue Paul Vaillant Couturier, 94807 Villejuif Cedex, France
    Circulation 115:840-5. 2007
    Oral estrogen therapy increases the risk of venous thromboembolism (VTE) in postmenopausal women. Transdermal estrogen may be safer...
  45. pmc Evaluation of the pattern of treatment, level of anticoagulation control, and outcome of treatment with warfarin in patients with non-valvar atrial fibrillation: a record linkage study in a large British population
    M Jones
    School of Mathematics, Cardiff University, Cardiff, UK
    Heart 91:472-7. 2005
    ..0-3.0 and to explore the relation between achieved INR control and clinical outcomes...
  46. pmc Comparison of risk stratification schemes to predict thromboembolism in people with nonvalvular atrial fibrillation
    Margaret C Fang
    Department of Medicine, University of California at San Francisco, San Francisco, California, USA
    J Am Coll Cardiol 51:810-5. 2008
    We assessed 5 risk stratification schemes for their ability to predict atrial fibrillation (AF)-related thromboembolism in a large community-based cohort.
  47. ncbi Silent thromboembolic events associated with the treatment of unruptured cerebral aneurysms by use of Guglielmi detachable coils: prospective study applying diffusion-weighted imaging
    G Rordorf
    Department of Neurology, Massachusetts General Hospital, Boston 02114, USA
    AJNR Am J Neuroradiol 22:5-10. 2001
    ..Although clinical sequelae are rare, the high rate of occurrence suggests that alterations in the technique, such as the addition of antiplatelet agents, should be considered...
  48. ncbi The risk of venous thromboembolism is markedly elevated in patients with diabetes
    V Petrauskiene
    Department of Public Health and Clinical Medicine, Umea University Hospital, 901 85 Umea, Sweden
    Diabetologia 48:1017-21. 2005
    Diabetes mellitus is associated with several changes in coagulation and fibrinolysis that may lead to a thrombogenic propensity. However, it is not known whether these perturbations actually cause increased risk of venous thromboembolism.
  49. doi Frequency of thromboembolic events associated with endovascular aneurysm treatment: retrospective case series
    Nathaniel P Brooks
    Department of Neurological Surgery, University of Wisconsin at Madison, WI, USA
    J Neurosurg 108:1095-100. 2008
    ..The authors report their experience with 155 aneurysms treated with and without adjunctive devices...
  50. ncbi Identification of patients at low risk for recurrent venous thromboembolism by measuring thrombin generation
    Gregor Hron
    Department of Internal Medicine I, Medical University of Vienna, Austria
    JAMA 296:397-402. 2006
    Screening of patients with venous thromboembolism (VTE) for thrombophilic risk factors is common clinical practice. Because of the large number of risk factors, assessing the risk of recurrence in an individual patient is complex...
  51. doi Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study
    Giancarlo Agnelli
    Internal and Vascular Medicine Stroke Unit, University of Perugia, Perugia, Italy
    Lancet Oncol 10:943-9. 2009
    ..with cancer who are receiving chemotherapy, since these patients are at an increased risk of developing a thromboembolism. We did a trial to assess the clinical benefit of the low-molecular-weight heparin nadroparin for the ..
  52. ncbi Venous thromboembolism during pregnancy: a retrospective study of enoxaparin safety in 624 pregnancies
    J Lepercq
    , , Paris, France
    BJOG 108:1134-40. 2001
    ..SAMPLE: Data from 624 pregnancies in 604 women between 1988 and 1997. The incidence of previous thromboembolism was 29.8%, known thrombophilia 15.2%...
  53. ncbi Risk factors for chemotherapy-associated venous thromboembolism in a prospective observational study
    Alok A Khorana
    James P Wilmot Cancer Center and the Department of Medicine, University of Rochester, New York, USA
    Cancer 104:2822-9. 2005
    The incidence of venous thromboembolism (VTE) is increased in cancer, but little information is available about risk factors in cancer patients on chemotherapy.
  54. ncbi Anticoagulation therapy for stroke prevention in atrial fibrillation: how well do randomized trials translate into clinical practice?
    Alan S Go
    Division of Research, Kaiser Permanente of Northern California, Oakland, CA 94612, USA
    JAMA 290:2685-92. 2003
    Warfarin has been shown to be highly efficacious for preventing thromboembolism in atrial fibrillation in randomized trials, but its effectiveness and safety in clinical practice is less clear.
  55. ncbi Decreased platelet aggregation, increased bleeding time and resistance to thromboembolism in P2Y1-deficient mice
    J E Fabre
    Department of Medicine, University of North Carolina, CB 7248, Chapel Hill, Thurston Bowles Bld, Durham, North Carolina, USA
    Nat Med 5:1199-202. 1999
    ..In vivo, the lack of P2Y1 expression increased bleeding time and protected from collagen- and ADP-induced thromboembolism. These findings support the hypothesis that the ATP receptor P2Y1 is a principal receptor mediating both ..
  56. doi Guidelines on the diagnosis and management of acute pulmonary embolism: the Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC)
    Adam Torbicki
    Department of Chest Medicine, Institute for Tuberculosis and Lung Diseases, Warsaw, Poland
    Eur Heart J 29:2276-315. 2008
    ..With the exception of severe air and fat embolism, the haemodynamic consequences of non-thrombotic emboli are usually mild. Treatment is mostly supportive but may differ according to the type of embolic material and clinical severity...
  57. ncbi Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism
    Paul M Ridker
    Center for Cardiovascular Disease Prevention and the Division of Preventive Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston 02215, USA
    N Engl J Med 348:1425-34. 2003
    Standard therapy to prevent recurrent venous thromboembolism includes 3 to 12 months of treatment with full-dose warfarin with a target international normalized ratio (INR) between 2.0 and 3.0...
  58. ncbi Thromboembolic complications in the nephrotic syndrome: pathophysiology and clinical management
    Rajni Singhal
    Department of Medicine, McMaster University, 25 Charlton Avenue East, Suite 708, Hamilton, Ontario, Canada L8N lY2
    Thromb Res 118:397-407. 2006
    Patients with the nephrotic syndrome are at increased risk of developing venous and arterial thromboembolism, the most common of which is renal vein thrombosis...
  59. pmc Frequency of adverse events in patients with poor anticoagulation: a meta-analysis
    Natalie Oake
    Department of Medicine, University of Ottawa, Ottawa, Ont
    CMAJ 176:1589-94. 2007
    ..To gauge the potential effect of improved anticoagulation control, we undertook to determine the proportion of anticoagulant-associated events that occur when INRs are outside the therapeutic range...
  60. ncbi Prediction of the risk of bleeding during anticoagulant treatment for venous thromboembolism
    P M Kuijer
    Center for Haemostasis, Thrombosis, Atherosclerosis, and Inflammation Research, University of Amsterdam, The Netherlands
    Arch Intern Med 159:457-60. 1999
    ..in a large independent cohort of patients who were treated with anticoagulant therapy for established venous thromboembolism to allow for quantitative assessment of the risks and benefits of the therapy and to adapt the patient's ..
  61. ncbi Risk of nonfatal venous thromboembolism in women using a contraceptive transdermal patch and oral contraceptives containing norgestimate and 35 microg of ethinyl estradiol
    Susan S Jick
    Boston Collaborative Drug Surveillance Program, Boston University School of Medicine, Lexington, MA 02421, USA
    Contraception 73:223-8. 2006
    There is concern that a new transdermal contraceptive patch containing ethinyl estradiol (EE) and the progestin norelgestromin increases the risk for venous thromboembolism (VTE) compared to previously marketed oral contraceptives (OCs).
  62. pmc Third generation oral contraceptives and risk of venous thrombosis: meta-analysis
    J M Kemmeren
    Julius Centre for General Practice and Patient Oriented Research, University Medical Centre Utrecht, PO Box 85500, 3508 GA Utrecht, Netherlands
    BMJ 323:131-4. 2001
    ..DESIGN: Meta-analysis. STUDIES: Cohort and case-control studies assessing risk of venous thromboembolism among women using oral contraceptives before October 1995...
  63. doi Thromboembolism in patients with advanced gastroesophageal cancer treated with anthracycline, platinum, and fluoropyrimidine combination chemotherapy: a report from the UK National Cancer Research Institute Upper Gastrointestinal Clinical Studies Group
    Naureen Starling
    Royal Marsden Hospital National Health Service Foundation Trust, Surrey and London, United Kingdom
    J Clin Oncol 27:3786-93. 2009
    ..Data concerning the prevalence of and outcomes related to thromboembolic events (TEs) in patients with advanced gastroesophageal cancer who are undergoing chemotherapy are limited...
  64. ncbi Comparison of risk factors for the competing risks of coronary heart disease, stroke, and venous thromboembolism
    Robert J Glynn
    Division of Preventive Medicine and the Channing Laboratory, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02215, USA
    Am J Epidemiol 162:975-82. 2005
    ..clarify uncertainties about the associations of atherosclerotic risk factors with the development of venous thromboembolism (VTE). For a median of 20...
  65. ncbi Warfarin exposure and the risk of thromboembolic and major bleeding events among medicaid patients with atrial fibrillation
    Luke Boulanger
    Boston Health Economics, Waltham, MA 02451, USA
    Ann Pharmacother 40:1024-9. 2006
    ..Outcomes of anticoagulation have been assessed in commercially insured populations, but similar data do not exist for Medicaid populations...
  66. ncbi Is long-term low-molecular-weight heparin acceptable to palliative care patients in the treatment of cancer related venous thromboembolism? A qualitative study
    Simon I R Noble
    Department of Palliative Medicine, Velindre Hospital, Whitchurch, Cardiff, UK
    Palliat Med 19:197-201. 2005
    Venous thromboembolism (VTE) is common in patients with terminal cancer. Current treatment practice with warfarin has a high incidence of complications, including bleeding, poor control and recurrent VTE...
  67. doi Risks of thromboembolism and bleeding with thromboprophylaxis in patients with atrial fibrillation: A net clinical benefit analysis using a 'real world' nationwide cohort study
    Jonas Bjerring Olesen
    Department of Cardiology, Post 635, Copenhagen University Hospital Gentofte, Niels Andersens Vej 65, 2900 Hellerup, Denmark
    Thromb Haemost 106:739-49. 2011
    ..VKA consistently lowered the risk of thromboembolism compared to ASA and no treatment; the combination of VKA+ASA did not yield any additional benefit...
  68. ncbi Risk of recurrent venous thromboembolism in patients with common thrombophilia: a systematic review
    Wai Khoon Ho
    Department of Haematology, Royal Perth Hospital and Centre for Clinical Research Excellence, University of Western Australia, Perth
    Arch Intern Med 166:729-36. 2006
    The 2 most common genetic polymorphisms that predispose to a first episode of venous thromboembolism (VTE) are factor V Leiden (FVL) and prothrombin G20210A...
  69. ncbi Venous thromboembolism prevention in gynecologic cancer surgery: a systematic review
    M Heather Einstein
    Department of Obstetrics and Gynecology, University of Wisconsin Hospital and Clinics, Madison, WI 53792, USA
    Gynecol Oncol 105:813-9. 2007
    ..pelvic surgery, and the presence of malignancy place gynecologic oncology patients at high risk for venous thromboembolism (VTE)...
  70. doi Venous and arterial thromboembolism in severe sepsis
    Robert L Levine
    Department of Neurosurgery, University of Texas School of Medicine at Houston, 6431 Fannin, MSB 7 142, Houston, TX 77030, USA
    Thromb Haemost 99:892-8. 2008
    The burden of thromboembolism (TE) in severe sepsis is largely unknown. We assessed the prevalence of venous and arterial TE in patients with severe sepsis over a four-week period...
  71. ncbi The ABO blood group genotype and factor VIII levels as independent risk factors for venous thromboembolism
    Isabel Tirado
    Hospital de la Santa Creu i Sant Pau, Departament d Hematologia, Unitat d Hemostàsia i Trombosis, Barcelona, Spain
    Thromb Haemost 93:468-74. 2005
    ..3; 95% CI: 1.3-4.1). In conclusion, high FVIII levels and non-O blood groups, likely those with the A1 allele, are independent risk factors for venous thromboembolism and should be considered in evaluating of thrombophilia.
  72. ncbi Venous thromboembolism in ovarian cancer
    Anne O Rodriguez
    Department of Obstetrics and Gynecology, University of California Davis, USA
    Gynecol Oncol 105:784-90. 2007
    To determine the incidence, time-course, and risk factors associated with the development of thromboembolism (VTE) in a population-based study of women with ovarian cancer.
  73. doi Dabigatran vs warfarin for radiofrequency catheter ablation of atrial fibrillation
    Jin Seok Kim
    Cardiovascular Medicine, University of Michigan, Ann Arbor, MI 48105 5853, USA
    Heart Rhythm 10:483-9. 2013
    ..It is not clear whether dabigatran is as safe and effective as uninterrupted anticoagulation with warfarin during radiofrequency catheter ablation (RFA) of atrial fibrillation (AF)...
  74. ncbi Incidence of venous thromboembolism following major abdominal surgery: a multi-center, prospective epidemiological study in Japan
    M Sakon
    Department of Surgery, Nishinomiya Municipal Central Hospital, Nishinomiya, Japan
    J Thromb Haemost 4:581-6. 2006
    Venous thromboembolism (VTE) has been considered to be a rare surgical complication in Japan.
  75. ncbi Short-duration prophylaxis against venous thromboembolism after total hip or knee replacement: a meta-analysis of prospective studies investigating symptomatic outcomes
    James D Douketis
    Department of Medicine, McMaster University, and St Joseph s Hospital, Hamilton, Ontario, Canada L8N 4A6
    Arch Intern Med 162:1465-71. 2002
    ..We performed a meta-analysis to provide reliable estimates of the risk of symptomatic venous thromboembolism occurring within 3 months of hip or knee replacement in patients who received short-duration (7-10 days) ..
  76. ncbi Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria
    Peter Hillmen
    Leeds General Infirmary, Leeds, United Kingdom
    Blood 110:4123-8. 2007
    ..In paroxysmal nocturnal hemoglobinuria (PNH) patients, hemolysis can contribute to thromboembolism (TE), the most feared complication in PNH, and the leading cause of disease-related deaths...
  77. ncbi Twice vs three times daily heparin dosing for thromboembolism prophylaxis in the general medical population: A metaanalysis
    Christopher S King
    Department of Medicine, Walter Reed Army Medical Center, 6900 Georgia Ave NW, Washington, DC 20307, USA
    Chest 131:507-16. 2007
    Prophylaxis with unfractionated heparin (UFH) has been proven to reduce rates of venous thromboembolism (VTE) in hospitalized medical patients...
  78. ncbi Prophylaxis of venous thromboembolism using two different doses of low-molecular-weight heparin (nadroparin) in bariatric surgery: a prospective randomized trial
    F Kalfarentzos
    Nutrition Support and Morbid Obesity Clinic, University of Patras, Platia Voriou Ipirou 5, 264 41 Patras, Greece
    Obes Surg 11:670-6. 2001
    ..In morbidity obese patients, the limited number of comparative trials are too sparse to allow a consensus on the effective dose and dosing schedule...
  79. ncbi Thromboembolic events in children with acute lymphoblastic leukemia (BFM protocols): prednisone versus dexamethasone administration
    Ulrike Nowak-Gottl
    Pediatric Hematology Oncology, University Hospital Munster, Germany
    Blood 101:2529-33. 2003
    Alterations in hemostasis leading to symptomatic thromboembolism have been observed in patients with acute lymphoblastic leukemia (ALL) receiving Escherichia coli asparaginase (CASP) combined with steroids...
  80. ncbi Efficacy of antithrombotic therapy in chronic heart failure: the HELAS study
    Dennis V Cokkinos
    Cardiology Department, Hippokrateio Hospital, University of Athens, Athens, Greece
    Eur J Heart Fail 8:428-32. 2006
    It is not clear if long-term antithrombotic treatment has a beneficial effect on the incidence of thromboembolism in chronic heart failure (CHF)...
  81. ncbi Incidence of symptomatic venous thromboembolism after different elective or urgent surgical procedures
    Richard H White
    Division of General Medicine, University of California, Davis, California, USA
    Thromb Haemost 90:446-55. 2003
    ..Because of the high incidence of VTE diagnosed after hospital discharge, further studies of extended thromboprophylaxis appear warranted...
  82. doi Prevalence and predictors of warfarin use in patients with atrial fibrillation at low or intermediate risk and relation to thromboembolic events
    Sanders H Chae
    Department of Cardiovascular Medicine, University of South Florida, Tampa, Florida, USA
    Clin Cardiol 34:640-4. 2011
    ..The purpose of this study was to determine the predictors of warfarin use in patients with AF at low (CHADS(2) =0) or intermediate (CHADS(2) =1) risk for TEs...
  83. doi A randomized phase II trial of apixaban for the prevention of thromboembolism in patients with metastatic cancer
    M N Levine
    Department of Oncology, McMaster University and Ontario Clinical Oncology Group, Hamilton, Ontario, Canada
    J Thromb Haemost 10:807-14. 2012
    ..Cancer patients receiving chemotherapy are at increased risk for thrombosis. Apixaban, a factor Xa inhibitor, is oral and does not require laboratory monitoring...
  84. ncbi Thrombin-activatable fibrinolysis inhibitor and the risk for recurrent venous thromboembolism
    Sabine Eichinger
    Department of Internal Medicine I, University of Vienna, Vienna, Austria
    Blood 103:3773-6. 2004
    The impact of fibrinolysis for predicting the risk for recurrent venous thromboembolism (VTE) is low...
  85. pmc Automatic computation of CHA2DS2-VASc score: information extraction from clinical texts for thromboembolism risk assessment
    Cyril Grouin
    LIMSI CNRS, F 91043 Orsay, France
    AMIA Annu Symp Proc 2011:501-10. 2011
    ..6%, and the accuracy of the 21 CHA2DS2-VASc scores was 85.7%. All differences in scores trigger the same alert, which means that system performance on this test set yields similar results to human reading of the texts...
  86. doi Possible refinement of clinical thromboembolism assessment in patients with atrial fibrillation using echocardiographic parameters
    Rui Providencia
    Cardiology Department, Coimbra s Hospital Center and University, Coimbra, Portugal
    Europace 14:36-45. 2012
    ....
  87. doi Mechanical characterization of thromboemboli in acute ischemic stroke and laboratory embolus analogs
    J Y Chueh
    Department of Radiology, New England Center for Stroke Research, University of Massachusetts Medical School, Worcester, Massachusetts, USA
    AJNR Am J Neuroradiol 32:1237-44. 2011
    ..We characterized the mechanical properties and composition of thromboemboli from clinical cases and compared them with commonly used EAs...
  88. ncbi The epidemiology of venous thromboembolism in the community
    J A Heit
    Division of Cardiovascular Diseases, Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA
    Thromb Haemost 86:452-63. 2001
    The incidence of venous thromboembolism exceeds 1 per 1000; over 200,000 new cases occur in the United States annually. Of these, 30% die within 30 days; one-fifth suffer sudden death due to pulmonary embolism...
  89. ncbi Prospective study of subclinical atherosclerosis as a risk factor for venous thromboembolism
    L M Reich
    Division of Epidemiology and Community Health, School of Public Health, University of Minnesota, Minneapolis, 55454 1015, USA
    J Thromb Haemost 4:1909-13. 2006
    ..Whether atherosclerotic disease predisposes to venous thrombosis is uncertain...
  90. pmc Effects of the direct thrombin inhibitor dabigatran on ex vivo coagulation time in orthopaedic surgery patients: a population model analysis
    Karl Heinz Liesenfeld
    Boehringer Ingelheim Pharma GmbH and Co, KG, Ingelheim, Germany
    Br J Clin Pharmacol 62:527-37. 2006
    ....
  91. ncbi Thromboembolism in children with sarcoma
    Uma Athale
    Department of Pediatrics, Division of Hematology, McMaster University, Hamilton, Ontario, Canada
    Pediatr Blood Cancer 49:171-6. 2007
    b>Thromboembolism (TE) is a common complication and cause of death in adults with cancer. Cancer has been identified as a major risk factor in children with TE...
  92. ncbi Low vitamin B6 levels and the risk of recurrent venous thromboembolism
    Gregor Hron
    Unita di Ematologia e Trombosi, Ospedale San Paolo, Dipartimento di Medicina, Chirurgia e Odontoiatria, Universita di Milano, Milano, Italy
    Haematologica 92:1250-3. 2007
    ..vitamin B6, measured as pyridoxal-5'-phosphate (PLP), is associated with an increased risk of first venous thromboembolism (VTE)...
  93. doi Presence and duration of atrial fibrillation detected by continuous monitoring: crucial implications for the risk of thromboembolic events
    Giovanni L Botto
    Cardiology Department, S Anna Hospital, Como, Italy
    J Cardiovasc Electrophysiol 20:241-8. 2009
    ..The secondary objective was to compare intermittent versus continuous monitoring strategies...
  94. doi Intraarterial abciximab for treatment of thromboembolism during coil embolization of intracranial aneurysms: outcome and fatal hemorrhagic complications
    Jae Hyo Park
    Department of Neurosurgery, Seoul National University College of Medicine, Jongno gu, Seoul, Korea
    J Neurosurg 108:450-7. 2008
    Experience with intraarterial abciximab for the treatment of thromboembolism during endovascular coil embolization is limited...
  95. ncbi Venous thromboembolism: disease burden, outcomes and risk factors
    J A Heit
    Division of Cardiovascular Diseases Section of Vascular Diseases, Department of Internal Medicine, Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
    J Thromb Haemost 3:1611-7. 2005
    The epidemiology of venous thromboembolism (VTE) in the community has important implications for VTE prevention and management...
  96. ncbi Epidemiology of venous thromboembolism in 9489 patients with malignant glioma
    Thomas J Semrad
    Department of Internal Medicine, University of California Davis School of Medicine, Sacramento, California 95817, USA
    J Neurosurg 106:601-8. 2007
    The authors sought to define the incidence of symptomatic venous thromboembolism (VTE) in patients harboring malignant gliomas.
  97. ncbi Thromboembolic complications in children with cancer
    John T Wiernikowski
    Division of Hematology Oncology, McMaster Children s Hospital Hamilton, Ontario, Canada
    Thromb Res 118:137-52. 2006
    Thrombosis is a significant problem in patients with cancer. The impact of thromboembolism in association with childhood cancer is not clearly defined...
  98. ncbi High absolute risks and predictors of venous and arterial thromboembolic events in patients with nephrotic syndrome: results from a large retrospective cohort study
    Bakhtawar K Mahmoodi
    Division of Hemostasis, Thrombosis, and Rheology, Department of Hematology, University Medical Center Groningen, Groningen, The Netherlands
    Circulation 117:224-30. 2008
    No data are available on the absolute risk of either venous thromboembolism (VTE) or arterial thromboembolism (ATE) in patients with nephrotic syndrome...
  99. pmc Risk of thromboembolism following acute intracerebral hemorrhage
    Joshua N Goldstein
    Department of Emergency Medicine, Massachusetts General Hospital, Zero Emerson Place, Suite 3B, Boston, MA 02114, USA
    Neurocrit Care 10:28-34. 2009
    ..We hypothesized that TEs are relatively common following ICH, and that anticoagulated patients are at higher risk for these complications...
  100. ncbi Ultrasound in the detection of venous thromboembolism
    Michael Blaivas
    Department of Emergency Medicine, Medical College of Georgia, Northside Hospital Forsyth, Atlanta, GA, USA
    Crit Care Med 35:S224-34. 2007
    ..out deep venous thrombosis is exacerbated by increased susceptibility that critically ill patients have to thromboembolism. Lower extremity venous ultrasound use by clinicians has been well studied and has proven both reliable and ..
  101. ncbi Effects of giant left atrium on thromboembolism after mitral valve replacement
    Veysel Kutay
    Cardiovascular Surgery Department, Van Yuksek Ihtisas Hospital, Van, Turkey
    Asian Cardiovasc Thorac Ann 13:107-11. 2005
    ..3 mm to 6.2 +/- 1.6 mm ( p < 0.01). There were no significant differences in thrombosis, hemorrhage and thromboembolism rates in both groups...

Research Grants76

  1. Effectiveness and Safety of Antithrombotic Strategies after Joint Replacement
    Elaine Hylek; Fiscal Year: 2013
    DESCRIPTION (provided by applicant): Venous thromboembolism (VTE) accounts for 100,000-180,000 deaths, greater than 250,000 hospitalizations, and between $13,000 and $20,000 annually per event in the United States...
  2. Microvascular Dysfunction in Hyperhomocysteinemia
    Shawn E Bearden; Fiscal Year: 2012
    ..of the microvascular dysfunction caused by HHcy, a risk factor for cardiovascular disease, venous thromboembolism, stroke, and Alzheimer disease...
  3. Role of Lipoproteins in Chagasic heart disease
    JYOTHI FALGUNI NAGAJYOTHI; Fiscal Year: 2013
    ..prominent fibrotic scarring, cardiac hypertrophy, arrhythmia, cardiomyopathy, heart failure and secondary thromboembolism. Mortality due to cardiovascular disease is increasing in the most developed countries of South and Central ..
  4. Anti-Phospholipid Multiplex For Pathologic Epitopes
    Paul O Neilsen; Fiscal Year: 2010
    ..venous thrombosis/embolism;and secondary APS compounds other autoimmune diseases such as lupus and venous thromboembolism. Women with APS are at higher risk for preeclampsia, preterm birth, and recurrent pregnancy loss...
  5. Reasons for Racial Disparities in Venous Thromboembolism
    NEIL ADRIAN ZAKAI; Fiscal Year: 2010
    ..to Prevent Deep Venous Thrombosis and Pulmonary Embolism, over 300,000 Americans each year suffer from venous thromboembolism (VTE), with potentially over 100,000 fatalities per year. VTE is approximately 1...
  6. FOCUS
    JEFFREY LEE CARSON; Fiscal Year: 2011
    ..and postoperative complications (death in hospital or within 30 days, pneumonia, myocardial infarction, thromboembolism, stroke, delirium). We will randomize 2,600 patients from 25 centers over a 3.5-year period...
  7. Recombinant and Chemo-/Bio-Orthogonal Synthesis of Liposomal Thrombomodulin
    Xue Long Sun; Fiscal Year: 2013
    DESCRIPTION (provided by applicant): Thrombotic diseases such as myocardial infarction, stroke, and thromboembolism are severe with significant mortality and morbidity in the United States...
  8. Smooth Muscle Cell Tissue Factor and Cardiovascular Disease
    Mark B Taubman; Fiscal Year: 2013
    ..Tissue factor is thought to play a major role in coronary thrombosis, the leading cause of heart attacks, and venous thromboembolism, the second leading cause of death in patients with cancer.
  9. Physiology and Molecular Biology of Factor XI
    David Gailani; Fiscal Year: 2013
    ..of the fXI anion binding sites to fXI activity in two models of arterial thrombosis, and one model of venous thromboembolism, in mice;and will assess the possibility that the anion binding sites are involved in establishing non-..
  10. Factor XI in Thrombosis
    David Gailani; Fiscal Year: 2013
    ..by human population data, strongly indicate that fXI makes important contributions to pathologic coagulation (thromboembolism)...
  11. Genetic and Environmental Risk Factors for Venous Thromboembolism
    Christopher Kabrhel; Fiscal Year: 2013
    DESCRIPTION (provided by applicant): Background: Venous thromboembolism (VTE) strikes 1-2/1000 Americans annually, and is a common cause of cardiovascular death...
  12. Novel Anti-infective and Anti-thrombotic Micro-patterned Central Venous Catheter
    SHRAVANTHI REDDY; Fiscal Year: 2012
    ..S. alone, and catheter-related thrombosis (CRT), which can lead to thromboembolism, a major contributor to in-hospital mortality...
  13. An Integrative Systems Genetics Approach to Nephrotic Syndrome
    MATTHEW GORDON SAMPSON; Fiscal Year: 2013
    ..This proteinuria is accompanied by increased risk of infection, venous thromboembolism, and progressive loss of renal function...
  14. Women's Health Study: Continued Follow-Up
    Julie E Buring; Fiscal Year: 2010
    ..myocardial infarction, ischemic stroke, coronary heart disease, congestive heart failure, and venous thromboembolism. The primary aim is to develop improved prediction scores for total and specific CVD outcomes that are based ..
  15. Factor XI inhibitor for thrombosis
    ERIK IAN TUCKER; Fiscal Year: 2013
    DESCRIPTION (provided by applicant): Thrombotic cardiovascular diseases including venous thromboembolism (VTE), deep vein thrombosis (DVT), myocardial infarction, and ischemic stroke, remain leading causes of death and disability in the ..
  16. Novel Methods for Dissolving Blood Clots
    GUY LELAND REED; Fiscal Year: 2013
    DESCRIPTION (provided by applicant): Each year, as many as 2 million Americans develop venous thromboembolism (VTE). VTEs are blood clots in the legs (venous thrombosis) that may travel to the lungs (pulmonary embolism)...
  17. Identifying novel genetic risk factors for venous thromboembolism (VTE)
    Jun Li; Fiscal Year: 2013
    ..by applicant): Deep vein thrombosis (DVT) and pulmonary embolism (PE), collectively referred to as venous thromboembolism (VTE), is the third most common cause of vascular death in the US, after only heart attacks and strokes...
  18. Structural origin of fibrin clot mechanical properties
    John W Weisel; Fiscal Year: 2012
    ..tend to be associated with bleeding, while very stiff clots have been associated with thrombosis and thromboembolism, which cause heart attacks and strokes...
  19. Development of a Pediatric Ventricular Assist Device
    Robert Jarvik; Fiscal Year: 2009
    ..The few device related infections that occurred were all successfully treated. Some thrombus, thromboembolism, and hemolysis has occurred, but at an acceptably low incidence...
  20. Antithrombotic Therapy and Prevention of Thrombosis: ACCP Evidence-Based Clinical
    Sandra Zelman Lewis; Fiscal Year: 2010
    ..Clinical Practice Guidelines, 9th Edition Development Conference The 900,000 annual cases of venous thromboembolism (VTE) in the US account for approximately 250,000 hospitalizations, with subsequent mortality in a large ..
  21. Mechanisms of Venous Thromboembolism in Cancer
    Nigel Mackman; Fiscal Year: 2012
    Venous thromboembolism (VTE) is a leading cause of death and disability in cancer patients...
  22. 2012 CRTI Summer Workshop
    Mark Crowther; Fiscal Year: 2012
    ..of Americans;hematological malignancies are estimated to result in over 50,000 deaths in 2011, and venous thromboembolism will result in 200,000 deaths...
  23. Anatomic Risk Factors for Venous Thromboembolism
    ANAND KUMAR NARAYAN; Fiscal Year: 2010
    ..With this grant, we hope to use new imaging techniques to determine who is at risk for DVT so that we can prevent people from developing DVT. ..
  24. FOCUS Data Coordinating Center
    Michael L Terrin; Fiscal Year: 2010
    ..and postoperative complications (death in hospital or within 30 days, pneumonia, myocardial infarction, thromboembolism, stroke). We will randomize 2,600 patients over a 3...
  25. Microvesicle production after trauma &its Clinical Impact on Venothromboembolism
    Myung S Park; Fiscal Year: 2013
    ..vein thrombosis) or clots lodged in the lung (also known as pulmonary embolism), collectively known as venous thromboembolism. In the United States alone, there are over 900,000 cases per year of deep vein thrombosis and pulmonary ..
  26. Griffin: Venous Thromboembolism and mass spectrometry-based untargeted metabolomi
    JOHN H contact GRIFFIN; Fiscal Year: 2010
    ..To discover new biomarkers for risk of VTE, we will screen >3,500 metabolites normally found in blood plasma from approximately 1,000 VTE subjects using pioneering state-of-the-art mass spectrometry based technologies. ..
  27. Surgical Treatment Outcomes for Patients with Psychiatric Disorders (STOPP)
    Laurel A Copeland; Fiscal Year: 2013
    ..3) Assess 30-day, 90-day, and 1-year postoperative complications (e.g., heart attack, venous thromboembolism, ICU admission, pneumonia, respiratory failure, sepsis, wound infection) by SMI status. Methods...
  28. EPIDEMIOLOGY OF VENOUS THROMBOSIS AND PULMONARY EMBOLISM
    Aaron R Folsom; Fiscal Year: 2013
    DESCRIPTION (provided by applicant): Venous thromboembolism (VTE), comprising deep venous thrombosis and pulmonary embolism, is a major contributor to morbidity and mortality in the U.S...
  29. Microparticle Docking in Pancreatic Cancer Induced VTE
    Julia E Geddings; Fiscal Year: 2013
    DESCRIPTION (provided by applicant): Venous thromboembolism (VTE) is a clinical term which refers to the development of deep vein thrombosis and pulmonary embolism...
  30. Older Adult Safety in Surgery (OASIS)
    Alok Kapoor; Fiscal Year: 2012
    ..The proposal uses venous thromboembolism (VTE) prophylaxis after total hip and knee replacement as a first case example of a method which may be ..
  31. p16INK4a, Senescence and Aging in Venous Thromboembolism
    FRANK CHURCH; Fiscal Year: 2009
    ..Independent of other risk factors, increasing age is linked to an increase in venous thrombosis and venous thromboembolism. The cell cycle inhibitor protein, p16INK4a, effects an anti- cancer tumor suppressor activity and a pro-..
  32. Infection and Inflammation in Pediatric Catheter Related Venous Thrombosis
    Leslie J Raffini; Fiscal Year: 2012
    ..The presence of a central venous catheter (CVC) is the single most important risk factor for venous thromboembolism (VTE) is children...
  33. Novel Therapeutic Targets for Venous Thromboembolism
    THOMAS WILLIAM WAKEFIELD; Fiscal Year: 2012
    Abstract: Venous thromboembolism (VTE;DVT/PE) is a national health concern, with an occurrence of over 900,000 cases per year and over 300,000 deaths per year, more than breast cancer and AIDs combined...
  34. Platelet activation by cocaine in HIV-1 patients involves IKK
    MICHELLE MEGAN KIEBALA; Fiscal Year: 2013
    ..These thrombotic complications, which can include atherosclerosis, venous thromboembolism (VTE), and myocardial infarction, are further exacerbated by cocaine use among HIV infected individuals...
  35. Center for Health Insurance Reform, Cardiovascular Outcomes, and Disparities
    Nancy R Kressin; Fiscal Year: 2013
    ..The second project will examine care and outcomes of care for venous thromboembolism (VTE) both pre- and post-reform, examining whether increased access to primary and home care, and to ..
  36. Optimizing Prophylaxis Against Venous Thromboembolism in Bariatric Surgery
    Nancy J Birkmeyer; Fiscal Year: 2012
    ..Although bariatric surgery has become safer over time, venous thromboembolism (VTE) remains a major cause of potentially preventable morbidity and mortality...
  37. Homocysteine &Heme: A Role in Thrombosis?
    Jan P Kraus; Fiscal Year: 2012
    ..levels of homocysteine and decreased levels of cysteine and glutathione and a profoundly enhanced risk of thromboembolism and stroke...
  38. Novel Device for Sensitive, Small Sample Volume Assessment of Clot Elasticity
    Amy L Oldenburg; Fiscal Year: 2012
    ..array of cardiovascular disorders including myocardial infarction, stroke, coronary artery disease, venous thromboembolism, and hyperglycemia...
  39. Molecular Mechanisms of Adverse Metabolic Events by Asparaginase.
    Tracy G Anthony; Fiscal Year: 2013
    ..complications that include fatty liver, reduced plasma proteins, and coagulation problems that lead to thromboembolism and cerebrovascular events. Our long-term goal is to increase the safety and efficacy of asparaginase...
  40. DEVELOPMENT OF A FIRST-IN-CLASS TARGETED FIBRINOLYTIC FOR POST-SURGICAL THROMBOPR
    Ronald Carnemolla; Fiscal Year: 2013
    ..Two thirds of venous thromboembolism (VTE) cases and deaths are hospital-acquired and is the most common preventable cause of hospital death and ..
  41. iPSC-Derived Cardiomyocytes in Left Ventricular Non-Compaction Cardiomyopathy
    Daniel Bernstein; Fiscal Year: 2013
    ..of both systolic and diastolic dysfunction, as well as with ventricular arrhythmias, mural thrombi and thromboembolism. Similar to other cardiomyopathies, LVNC has been associated with mutations in multiple cytoskeletal, ..
  42. Contemporary Treatment and Outcomes for Atrial Fibrillation in Clinical Practice
    DANIEL EDWIN SINGER; Fiscal Year: 2010
    ..arrhythmia in adults and one of the most potent risk factors for ischemic stroke and other systemic thromboembolism. It affects 2...
  43. Anti-fibrotic Coatings for Rapidly Exchangeable Bioprosthetic Heart Valve
    Ivan Vesely; Fiscal Year: 2010
    ..Detailed measurements of fibrotic overgrowth and incidence of thromboembolism will be examined at necropsy...
  44. Middle cerebral artery stroke: Non-contrast MR screening of high-risk plaque
    Chun Yuan; Fiscal Year: 2013
    ..Beyond luminal stenosis measurement, detection of atherosclerotic plaque at high-risk for causing thromboembolism, is not a part of routine stroke workup...
  45. BRIDGE TRIAL
    Thomas L Ortel; Fiscal Year: 2013
    ..This empiric strategy has several drawbacks, including lack of proven efficacy to prevent arterial thromboembolism, additional cost to the healthcare system, and the potential for increased peri-operative bleeding...
  46. BRIDGE TRIAL
    Victor Hasselblad; Fiscal Year: 2013
    ..This empiric strategy has several drawbacks, including lack of proven efficacy to prevent arterial thromboembolism, additional cost to the healthcare system, and the potential for increased peri-operative bleeding...
  47. Heparan Sulfate in Skeletal Development and Diseases
    Yu Yamaguchi; Fiscal Year: 2012
    ..In the adults, long-term heparin treatment for patients with thromboembolism and other vascular diseases often leads to a low bone mass condition resembling osteoporosis...
  48. Identifying CT Imaging Biomarkers Associated with Prognosis of Pulmonary Embolism
    Kyongtae T Bae; Fiscal Year: 2012
    ..applicant): Identifying CT Imaging Biomarkers Associated with Prognosis of Pulmonary Embolism Abstract Venous thromboembolism (VTE), which clinically manifests as deep vein thrombosis (DVT) and pulmonary embolism (PE), is a common but ..
  49. Genetic and Environmental Determinants of Warfarin Response
    Nita A Limdi; Fiscal Year: 2012
    ..Aim 3 will determine the association between candidate genes and risk of hemorrhage or thromboembolism. The study will also explore gene*gene and gene*non-genetic covariate interactions...
  50. Synthesis and Study of Novel Sensing Agents
    Robert M Strongin; Fiscal Year: 2010
    ..homocysteine (Hcy) levels are associated with increased risk of myocardial infarction, stroke and venous thromboembolism. Homocysteine has also been linked to increased risk of Alzheimer's disease, neural tube defects and ..
  51. Endothelial cell phosphatidylserine, topography, and procoagulant activity
    Gary E Gilbert; Fiscal Year: 2013
    ..hemorrhage and also contributes to thrombotic diseases including myocardial infarction, stroke, and venous thromboembolism. A great deal has been learned about blood coagulation on the scale of a test tube, an artery, and a vein...
  52. CCTN - CONTRACEPTIVE EFFICACY AND SAFETY OF DAILY ORAL ULIPRISTAL ACETATE
    ERIN ALLEN; Fiscal Year: 2013
    There is a demand for estrogen-free contraception in order to reduce the risk of venous thromboembolism (VTE), particularly for obese women...
  53. CCTN - CONTRACEPTIVE EFFICACY AND SAFETY OF DAILY ORAL ULIPRISTAL ACETATE
    ERIN ALLEN; Fiscal Year: 2013
    There is a demand for estrogen-free contraception in order to reduce the risk of venous thromboembolism (VTE), particularly for obese women...
  54. Venous Thromboembolism Risk Marker Assay
    DAVID HENRY FARRELL; Fiscal Year: 2012
    ..clinical assay for 3'fibrinogen that will be used to assess the risk of a patient developing venous thromboembolism. This assay will guide clinical management, particularly the use of long-term anticoagulant therapy for ..
  55. Venous Thrombosis in Cancer Outpatients: Prevention and Role of Tissue Factor
    Charles W Francis; Fiscal Year: 2012
    Venous thromboembolism (VTE) is a major problem in patients with cancer, contributing to mortality and morbidity, interfering with optimum treatment and resulting in high costs...
  56. Prediction of warfarin dosing using clinical and genetic factors
    Stephen E Kimmel; Fiscal Year: 2012
    b>Thromboembolism can occur in the venous or arterial system and is associated with substantial morbidity and mortality...
  57. Novel Platelet Functions in Sepsis and Venous Thromboembolism
    MATTHEW THOMAS RONDINA; Fiscal Year: 2013
    ..I will determine if these platelet activities and functions predict 28-day mortality, overt DIG, and venous thromboembolism (VTE) in sepsis patients. I will also compare these platelet activities in sepsis patients to health controls...
  58. Determinants of T Cell Fate in Transplantation
    Mandy L Ford; Fiscal Year: 2012
    ..Unfortunately, the anti-CD154 mAbs that are a cornerstone of this approach cause platelet dysfunction and thromboembolism. In addition, the presence of donor-specific memory T cells as a result of heterologous immunity present a ..
  59. Long Circulating Low Molecular Weight Heparins Pulmonary
    Fakhrul Ahsan; Fiscal Year: 2006
    unreadable] DESCRIPTION (provided by applicant): Venous thromboembolism (VTE) is a fatal blood clotting disorder that affects up to two people per 1000 each year in the United States resulting in more than 600,000 hospitalizations and ..
  60. Genetic Epidemiological Study of Venous Thromboembolism and Hemostatic Factors
    Weihong Tang; Fiscal Year: 2012
    Venous thromboembolism (VTE) is a common disease and an important public health problem...
  61. Venous thromboembolism among California cancer patients
    Helen Chew; Fiscal Year: 2003
    Venous thromboembolism (VTE, includes both venous thrombosis and pulmonary embolism) is a frequent complication among patients with cancer...
  62. Constrictor / Mitogen Induced Remodeling of Cerebral Arterioles
    JAY HUMPHREY; Fiscal Year: 2009
    ..These additional key factors may include acute brain injury, thromboembolism of small vessels, cortical spreading depression, and of particular note herein, microcirculatory dysfunction...
  63. Cost Effectiveness of Anticoagulation Versus Genetic Testing of CYP2C9 & VKORC1 G
    Anna Teschemaker; Fiscal Year: 2009
    DESCRIPTION (provided by applicant): Long-term clinical follow-up of venous thromboembolism (VTE) can be complicated by excess morbidity and mortality...
  64. INFERIOR VENA CAVA FILTRATION WITH A REMOVABLE DEVICE
    Elvira Lang; Fiscal Year: 1999
    ..PROPOSED COMMERCIAL APPLICATION: Risk factors for pulmonary thromboembolism include immobilization, orthopedic or abdominal surgery, spinal cord injury, multiple trauma, cardiac disease ..
  65. Libman-Sacks Endocarditis and NPSLE
    Carlos Roldan; Fiscal Year: 2009
    ..3, 95% Cl 1.7 - 139, p = 0.005). Thus, thromboembolism from valve vegetations is likely a major cause of NPSLE...
  66. ORAL CONTRACEPTIVES AND THROMBOEMBOLIC DISEASE
    Stephen Sidney; Fiscal Year: 2000
    ..to obtain detailed information about OC use and other factors that may influence the development of venous thromboembolism. Blood specimens will be analyzed for presence of the Factor V Leiden mutation, the most common known ..
  67. MUTATIONS, HORMONE THERAPY, AND VENOUS THROMBOEMBOLISM
    Bruce Psaty; Fiscal Year: 2001
    ..heritable thrombophilia a prothrombotic mutation associated with a 5 to 7-fold increase in the risk of venous thromboembolism (VTE)...
  68. Pharmacologic treatment of thromboembolism
    TZE CHEIN WUN; Fiscal Year: 2009
    ..This project will conduct pre-clinical studies of a novel anticoagulant protein for the experimental treatment of arterial and venous thrombosis. ..
  69. ER beta selective agonist coronary protection-menopause
    R Hermsmeyer; Fiscal Year: 2005
    ..Tissue Factor Pathway Inhibitor (TFPI) levels will be measured as an index of protection against thromboembolism. In addition, C-Reactive Protein (CRP) in serum and thromboxane B2 in urine will be used as adverse ..
  70. TAMOXIFEN--RISK OF MI, STROKE AND VENOUS THROMBOEMBOLISM
    Leslie Bernstein; Fiscal Year: 2001
    ....
  71. Biologic Ventricular Assist Device
    Robert Kloner; Fiscal Year: 2004
    ..as bridges to transplant and even may provide long-term benefits, they may develop mechanical difficulty, thromboembolism, infection, and require anticoagulation...
  72. INCIDENCE AND OUTCOMES OF VENOUS THROMBOEMBOLISM
    MARC SILVERSTEIN; Fiscal Year: 1993
    ....
  73. Procoagulant Microparticles: Novel Determinants of Venous Thrombosis
    THOMAS WILLIAM WAKEFIELD; Fiscal Year: 2011
    Venous thromboembolism (DVT) is a major healthcare problem causing significant morbidity and mortality...